TY - JOUR
T1 - Molecular pathways
T2 - Translational and therapeutic implications of the notch signaling pathway in cancer
AU - Previs, Rebecca A.
AU - Coleman, Robert L.
AU - Harris, Adrian L.
AU - Sood, Anil K.
N1 - Publisher Copyright:
© 2014 American Association for Cancer Research.
PY - 2015/3/1
Y1 - 2015/3/1
N2 - Over 100 years have passed since the first observation of the notched wing phenotype in Drosophila melanogaster, and significant progress has been made to characterize the role of the Notch receptor, its ligands, downstream targets, and cross-talk with other signaling pathways. The canonical Notch pathway with four Notch receptors (Notch1-4) and five ligands (DLL1, 3-4, Jagged 1-2) is an evolutionarily conserved cell signaling pathway that plays critical roles in cell-fate determination, differentiation, development, tissue patterning, cell proliferation, and death. In cancer, these roles have a critical impact on tumor behavior and response to therapy. Because the role of Notch remains tissue and context dependent, alterations within this pathway may lead to tumor suppressive or oncogenic phenotypes. Although no FDA-approved therapies currently exist for the Notch pathway, multiple therapeutics (e.g., demcizumab, tarextumab, GSI MK-0752, R04929097, and PF63084014) have been developed to target different aspects of this pathway for both hematologic and solid malignancies. Understanding the context-specific effects of the Notch pathway will be important for individualized therapies targeting this pathway.
AB - Over 100 years have passed since the first observation of the notched wing phenotype in Drosophila melanogaster, and significant progress has been made to characterize the role of the Notch receptor, its ligands, downstream targets, and cross-talk with other signaling pathways. The canonical Notch pathway with four Notch receptors (Notch1-4) and five ligands (DLL1, 3-4, Jagged 1-2) is an evolutionarily conserved cell signaling pathway that plays critical roles in cell-fate determination, differentiation, development, tissue patterning, cell proliferation, and death. In cancer, these roles have a critical impact on tumor behavior and response to therapy. Because the role of Notch remains tissue and context dependent, alterations within this pathway may lead to tumor suppressive or oncogenic phenotypes. Although no FDA-approved therapies currently exist for the Notch pathway, multiple therapeutics (e.g., demcizumab, tarextumab, GSI MK-0752, R04929097, and PF63084014) have been developed to target different aspects of this pathway for both hematologic and solid malignancies. Understanding the context-specific effects of the Notch pathway will be important for individualized therapies targeting this pathway.
UR - http://www.scopus.com/inward/record.url?scp=84929467875&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929467875&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-14-0809
DO - 10.1158/1078-0432.CCR-14-0809
M3 - Article
C2 - 25388163
AN - SCOPUS:84929467875
SN - 1078-0432
VL - 21
SP - 955
EP - 961
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 5
ER -